169 related articles for article (PubMed ID: 36701707)
1. NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden.
Li Z; Zheng Y; Wu Z; Zhuo T; Zhu Y; Dai L; Wang Y; Chen M
Medicine (Baltimore); 2023 Jan; 102(3):e32686. PubMed ID: 36701707
[TBL] [Abstract][Full Text] [Related]
2. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract][Full Text] [Related]
3. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
[TBL] [Abstract][Full Text] [Related]
4. NCPAD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer.
Feng L; Yang Y; Lin Z; Cui M; Jin A; Cui A
Genes Environ; 2024 Jan; 46(1):2. PubMed ID: 38172945
[TBL] [Abstract][Full Text] [Related]
5. Non-SMC Condensin I Complex Subunit D2 Is a Prognostic Factor in Triple-Negative Breast Cancer for the Ability to Promote Cell Cycle and Enhance Invasion.
Zhang Y; Liu F; Zhang C; Ren M; Kuang M; Xiao T; Di X; Feng L; Fu L; Cheng S
Am J Pathol; 2020 Jan; 190(1):37-47. PubMed ID: 31610177
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
7. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
8. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration.
Zhou H; Bian T; Qian L; Zhao C; Zhang W; Zheng M; Zhou H; Liu L; Sun H; Li X; Zhang J; Liu Y
Pathol Res Pract; 2021 Dec; 228():153680. PubMed ID: 34798483
[TBL] [Abstract][Full Text] [Related]
9. Non-SMC condensin I complex subunit D2 and non-SMC condensin II complex subunit D3 induces inflammation
Yuan CW; Sun XL; Qiao LC; Xu HX; Zhu P; Chen HJ; Yang BL
World J Gastroenterol; 2019 Dec; 25(47):6813-6822. PubMed ID: 31885422
[TBL] [Abstract][Full Text] [Related]
10. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma.
Hu A; Tang K; Liu J; Han X; Chen Q
Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
12. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
13. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
Wei S; Xing J; Lu K; Wang K; Yu W
Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
[TBL] [Abstract][Full Text] [Related]
14. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
15. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
[TBL] [Abstract][Full Text] [Related]
17. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
18. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.
Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B
World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488
[TBL] [Abstract][Full Text] [Related]
19. High Expression of
Deng H; Huang Y; Wang L; Chen M
Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]